AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Centerspace

$58.62 -$8.35 (-12.47%)
NYSE · 14 Sep 2026 20:00 UTC
Previous Close
$58.29
Day Range
$57.25$58.79
Year Range
$52$69.61
Market Cap
985M
AVG Volume
180.13K
Trailing/Forward PE
45.47/-
PEG ratio
-0.88
Dividend Yield
5.25%
Next Earnings Date
2026-11-02
Primary Exchange
New York Stock ExchangeUS
Revenue (USD)
020M40M60M80M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q265.78M
26 Q165.07M
25 Q466.62M
25 Q371.4M
25 Q268.55M
25 Q167.09M
24 Q466.41M
24 Q365.03M
24 Q265.04M
24 Q164.51M
Net Income (USD)
-20M020M40M60M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-962K
26 Q1-12.83M
25 Q4-18.38M
25 Q353.89M
25 Q2-14.36M
25 Q1-3.57M
24 Q4-4.92M
24 Q3-888K
24 Q2-1.14M
24 Q1-3.75M
Operating Income (USD)
-10M-5M05M10M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q28.58M
26 Q14.29M
25 Q43.7M
25 Q36.48M
25 Q2-6.8M
25 Q15.28M
24 Q42.86M
24 Q36.35M
24 Q27.19M
24 Q14.08M
EBITDA (USD)
050M100M150M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q234.57M
26 Q122M
25 Q419.84M
25 Q3107.83M
25 Q221.39M
25 Q133.42M
24 Q431.96M
24 Q333.38M
24 Q233.68M
24 Q131.72M
Cash Flows (USD)
010M20M30M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q215.07M
26 Q116.11M
25 Q412.71M
25 Q325.7M
25 Q215.54M
25 Q125.43M
24 Q49.45M
24 Q320.47M
24 Q29.09M
24 Q12.59M
EPS (USD)
-202424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-0.06
26 Q1-0.77
25 Q4-1.1
25 Q33.19
25 Q2-0.87
25 Q1-0.22
24 Q4-0.31
24 Q3-0.4
24 Q2-0.08
24 Q1-0.25
Expenses (USD)
010M20M30MSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q213.29M
26 Q111.65M
25 Q46.54M
25 Q314.35M
25 Q214.11M
25 Q110.04M
24 Q414.08M
24 Q315.95M
24 Q217.99M
24 Q126.43M
Cash & Debt (USD)
0500M1B1.5BCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q28.56M
26 Q17.55M
25 Q412.83M
25 Q312.9M
25 Q212.38M
25 Q111.92M
24 Q412.03M
24 Q314.45M
24 Q214.33M
24 Q112.68M
Debt ratios
02.557.51024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Debt ratios by quarter
PeriodDebt ratios
26 Q25.32
26 Q15.89
25 Q45.53
25 Q35.81
25 Q29.15
25 Q17.12
24 Q47.22
24 Q37.27
24 Q26.84
24 Q16.95
Margins
-25%0%25%50%75%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Margins by quarter
PeriodMargins
26 Q260.51%
26 Q1-24.4%
25 Q459.53%
25 Q356.77%
25 Q257.81%
25 Q156.53%
24 Q456.84%
24 Q355.55%
24 Q257.86%
24 Q157.52%
Return on Capital
-2.5%0%2.5%5%7.5%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Return on Capital by quarter
PeriodReturn on Capital
26 Q2-0.12%
26 Q1-1.57%
25 Q4-2.17%
25 Q36.08%
25 Q2-1.7%
25 Q1-0.41%
24 Q4-0.55%
24 Q3-0.1%
24 Q2-0.12%
24 Q1-0.41%
Shares Outstanding
05M10M15M20M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Shares Outstanding by quarter
PeriodShares Outstanding
26 Q216.81M
26 Q116.77M
25 Q416.73M
25 Q316.73M
25 Q216.74M
25 Q116.73M
24 Q416.58M
24 Q315.53M
24 Q214.97M
24 Q114.92M
Dividends (USD)
00.20.40.60.8Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
CSR Dividends (USD) by quarter
PeriodDividends (USD)
Sep 260.77
Jun 260.77
Mar 260.77
Dec 250.77
Sep 250.77
Jun 250.77
Mar 250.77
Dec 240.75
Sep 240.75
Jun 240.75
Employee Count
02004006002016201720182019202020212022202320242025
CSR Employee Count by quarter
PeriodEmployee Count
2025334
2024374
2023377
2022421
2021394
2020340
2019392
2018527
2017523
2016483
Book Value Per Share (USD)
02040608024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q247.47
26 Q148.65
25 Q450.56
25 Q353.03
25 Q250.47
25 Q152.61
24 Q454.21
24 Q358.29
24 Q261.1
24 Q161.9
Total Assets (USD)
01B2B3B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CSR Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q21.84B
26 Q11.89B
25 Q41.93B
25 Q32.1B
25 Q22.01B
25 Q11.89B
24 Q41.91B
24 Q31.89B
24 Q21.9B
24 Q11.9B
PE Ratio
050100150med 24.94Jul 23Nov 23Feb 24Nov 25Feb 26Jun 26Sep 26
CSR PE Ratio by quarter
PeriodPE Ratio
Sep 2645.36
Sep 2645.11
Sep 2640.94
Aug 2640.61
Aug 2641.76
Aug 2643.21
Aug 2643.86
Jul 26110.45
Jul 26112.24
Jul 26112.42
Jul 26111.92
Jul 26115.28
Jun 26114.8
Jun 26112.08
Jun 26117.6
Jun 26119.35
May 26135.91
May 26137.44
May 26134.88
May 26136.25
May 2665.04
Apr 2663.24
Apr 2661.92
Apr 2660.8
Apr 2656.97
Mar 2654.95
Mar 2654.26
Mar 2658.99
Mar 2660.01
Feb 2659.83
Feb 2659.1
Feb 2634.25
Feb 2634.62
Jan 2634.63
Jan 2634.54
Jan 2634.85
Jan 2635.87
Jan 2636.08
Dec 2536.21
Dec 2535.2
Dec 2535.29
Dec 2534.32
Nov 2535.97
Nov 2535.94
Nov 2536.03
Nov 2532.23
May 2424.23
May 2424.91
May 2425.12
May 2424.58
Apr 2423.11
Apr 2423.21
Apr 2421.73
Apr 2420.03
Mar 2420.44
Mar 2420.36
Mar 2420.08
Mar 2420.31
Mar 2420.03
Feb 2420.13
Feb 2417.59
Feb 2417.05
Feb 2417.04
Jan 2417.5
Jan 2417.81
Jan 2417.56
Jan 2417.01
Dec 2318.25
Dec 2318.15
Dec 2318.18
Dec 2317.09
Dec 2317.04
Nov 2316.99
Nov 2316.66
Nov 2316.09
Nov 2315.94
Oct 2318.23
Oct 2320.23
Oct 2321.52
Oct 2322.1
Sep 2322.97
Sep 2323
Sep 2323.79
Sep 2323.66
Sep 2324.43
Aug 2323.84
Aug 2323.05
Aug 2324.25
Aug 2324.43
Jul 2324.2
Jul 2325.4
Jul 2325.9
Jul 2324.86
Jun 2324.43
Jun 2323.11
Jun 2324.95
Jun 2324.92
Jun 2324.66
May 2323.4
May 2323.6
Free Cash Flow Yield
2%4%6%8%10%med 6.89%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CSR Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 267.06%
Sep 267.1%
Sep 267.83%
Aug 267.89%
Aug 267.67%
Aug 267.41%
Aug 267.3%
Jul 267.61%
Jul 267.49%
Jul 267.48%
Jul 267.51%
Jul 267.3%
Jun 267.33%
Jun 267.5%
Jun 267.15%
Jun 267.05%
May 266.19%
May 266.12%
May 266.24%
May 266.17%
May 266.94%
Apr 267.14%
Apr 267.29%
Apr 267.42%
Apr 267.92%
Mar 268.21%
Mar 268.32%
Mar 267.65%
Mar 267.52%
Feb 267.54%
Feb 267.64%
Feb 267.16%
Feb 267.08%
Jan 267.08%
Jan 267.1%
Jan 267.03%
Jan 266.83%
Jan 266.8%
Dec 256.77%
Dec 256.96%
Dec 256.95%
Dec 257.14%
Nov 256.82%
Nov 256.82%
Nov 256.81%
Nov 257.61%
Oct 257.15%
Oct 257.1%
Oct 257.03%
Oct 257.29%
Oct 257.18%
Sep 257.21%
Sep 257.26%
Sep 257.25%
Sep 257%
Aug 257.12%
Aug 257.28%
Aug 257.65%
Aug 257.91%
Aug 257.11%
Jul 256.69%
Jul 256.56%
Jul 256.41%
Jul 256.31%
Jun 256.41%
Jun 256.18%
Jun 256.06%
Jun 256.03%
May 256.04%
May 256.3%
May 256.09%
May 256.28%
May 256.27%
Apr 254.21%
Apr 254.34%
Apr 254.4%
Apr 254.17%
Mar 253.94%
Mar 253.93%
Mar 253.98%
Mar 253.82%
Feb 253.79%
Feb 253.91%
Feb 252.56%
Feb 252.59%
Jan 252.63%
Jan 252.62%
Jan 252.62%
Jan 252.65%
Jan 252.44%
Dec 242.43%
Dec 242.42%
Dec 242.3%
Dec 242.28%
Nov 242.21%
Nov 242.17%
Nov 242.2%
Nov 242.15%
Nov 242.39%
Oct 242.08%
Price to Sales
33.544.5med 3.84Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CSR Price to Sales by quarter
PeriodPrice to Sales
Sep 263.66
Sep 263.64
Sep 263.31
Aug 263.28
Aug 263.37
Aug 263.49
Aug 263.54
Jul 263.39
Jul 263.44
Jul 263.45
Jul 263.43
Jul 263.53
Jun 263.52
Jun 263.44
Jun 263.61
Jun 263.66
May 264.17
May 264.21
May 264.14
May 264.18
May 264.18
Apr 264.06
Apr 263.98
Apr 263.91
Apr 263.66
Mar 263.53
Mar 263.49
Mar 263.79
Mar 263.86
Feb 263.84
Feb 263.8
Feb 263.89
Feb 263.93
Jan 263.93
Jan 263.92
Jan 263.96
Jan 264.07
Jan 264.1
Dec 254.11
Dec 254
Dec 254.01
Dec 253.9
Nov 254.08
Nov 254.08
Nov 254.09
Nov 253.66
Oct 253.71
Oct 253.74
Oct 253.78
Oct 253.64
Oct 253.7
Sep 253.68
Sep 253.66
Sep 253.66
Sep 253.79
Aug 253.73
Aug 253.65
Aug 253.47
Aug 253.35
Aug 253.44
Jul 253.66
Jul 253.73
Jul 253.81
Jul 253.88
Jun 253.81
Jun 253.95
Jun 254.03
Jun 254.05
May 254.05
May 253.88
May 254.02
May 253.9
May 253.9
Apr 253.78
Apr 253.67
Apr 253.62
Apr 253.83
Mar 254.05
Mar 254.05
Mar 254.01
Mar 254.17
Feb 254.21
Feb 254.07
Feb 253.74
Feb 253.7
Jan 253.65
Jan 253.67
Jan 253.66
Jan 253.62
Jan 253.94
Dec 243.96
Dec 243.96
Dec 244.17
Dec 244.2
Nov 244.35
Nov 244.43
Nov 244.35
Nov 244.47
Nov 244.01
Oct 244.08
EV/EBITDA
1012141618med 14.54Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CSR EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 2610.67
Sep 2610.64
Sep 2610.15
Aug 2610.11
Aug 2610.25
Aug 2610.42
Aug 2610.5
Jul 2611.27
Jul 2611.36
Jul 2611.37
Jul 2611.34
Jul 2611.51
Jun 2611.48
Jun 2611.35
Jun 2611.62
Jun 2611.7
May 2612.51
May 2612.58
May 2612.46
May 2612.53
May 2611.79
Apr 2611.62
Apr 2611.49
Apr 2611.38
Apr 2611.02
Mar 2610.82
Mar 2610.75
Mar 2611.21
Mar 2611.31
Feb 2611.29
Feb 2611.22
Feb 2611.28
Feb 2611.33
Jan 2611.34
Jan 2611.32
Jan 2611.37
Jan 2611.54
Jan 2611.57
Dec 2511.59
Dec 2511.43
Dec 2511.44
Dec 2511.29
Nov 2511.55
Nov 2511.55
Nov 2511.56
Nov 2510.95
Oct 2517.4
Oct 2517.45
Oct 2517.54
Oct 2517.23
Oct 2517.37
Sep 2517.32
Sep 2517.27
Sep 2517.28
Sep 2517.57
Aug 2517.44
Aug 2517.25
Aug 2516.86
Aug 2516.6
Aug 2513.97
Jul 2514.4
Jul 2514.55
Jul 2514.71
Jul 2514.84
Jun 2514.71
Jun 2514.99
Jun 2515.15
Jun 2515.19
May 2515.18
May 2514.85
May 2515.12
May 2514.88
May 2514.88
Apr 2514.77
Apr 2514.54
Apr 2514.44
Apr 2514.85
Mar 2515.3
Mar 2515.31
Mar 2515.21
Mar 2515.54
Feb 2515.61
Feb 2515.35
Feb 2515.04
Feb 2514.95
Jan 2514.84
Jan 2514.88
Jan 2514.86
Jan 2514.78
Jan 2515.43
Dec 2415.47
Dec 2415.49
Dec 2415.92
Dec 2415.99
Nov 2416.3
Nov 2416.45
Nov 2416.3
Nov 2416.54
Nov 2415.58
Oct 2414.7
Price/Operating Cashflow
8910111213med 10.36Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CSR Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2610.72
Sep 2610.66
Sep 269.68
Aug 269.6
Aug 269.87
Aug 2610.22
Aug 2610.37
Jul 269.74
Jul 269.9
Jul 269.91
Jul 269.87
Jul 2610.17
Jun 2610.12
Jun 269.88
Jun 2610.37
Jun 2610.53
May 2611.99
May 2612.12
May 2611.89
May 2612.02
May 2611.62
Apr 2611.3
Apr 2611.06
Apr 2610.86
Apr 2610.18
Mar 269.82
Mar 269.69
Mar 2610.54
Mar 2610.72
Feb 2610.69
Feb 2610.56
Feb 2610.18
Feb 2610.29
Jan 2610.3
Jan 2610.27
Jan 2610.36
Jan 2610.67
Jan 2610.73
Dec 2510.77
Dec 2510.47
Dec 2510.49
Dec 2510.2
Nov 2510.69
Nov 2510.68
Nov 2510.71
Nov 259.58
Oct 259.76
Oct 259.82
Oct 259.92
Oct 259.56
Oct 259.72
Sep 259.66
Sep 259.6
Sep 259.62
Sep 259.96
Aug 259.8
Aug 259.58
Aug 259.11
Aug 258.81
Aug 259.13
Jul 259.71
Jul 259.9
Jul 2510.12
Jul 2510.29
Jun 2510.12
Jun 2510.5
Jun 2510.7
Jun 2510.76
May 2510.74
May 2510.31
May 2510.67
May 2510.34
May 2510.35
Apr 2510.05
Apr 259.75
Apr 259.62
Apr 2510.16
Mar 2510.76
Mar 2510.77
Mar 2510.64
Mar 2511.07
Feb 2511.17
Feb 2510.82
Feb 2510.56
Feb 2510.44
Jan 2510.29
Jan 2510.35
Jan 2510.33
Jan 2510.21
Jan 2511.1
Dec 2411.16
Dec 2411.18
Dec 2411.76
Dec 2411.86
Nov 2412.28
Nov 2412.48
Nov 2412.28
Nov 2412.61
Nov 2411.31
Oct 2411.55
Price to Book
11.11.21.31.41.5med 1.18Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
CSR Price to Book by quarter
PeriodPrice to Book
Sep 261.23
Sep 261.23
Sep 261.11
Aug 261.11
Aug 261.14
Aug 261.18
Aug 261.19
Jul 261.13
Jul 261.15
Jul 261.15
Jul 261.14
Jul 261.18
Jun 261.17
Jun 261.14
Jun 261.2
Jun 261.22
May 261.39
May 261.4
May 261.38
May 261.39
May 261.35
Apr 261.32
Apr 261.29
Apr 261.26
Apr 261.18
Mar 261.14
Mar 261.13
Mar 261.23
Mar 261.25
Feb 261.24
Feb 261.23
Feb 261.2
Feb 261.21
Jan 261.21
Jan 261.21
Jan 261.22
Jan 261.26
Jan 261.26
Dec 251.27
Dec 251.23
Dec 251.24
Dec 251.2
Nov 251.26
Nov 251.26
Nov 251.26
Nov 251.13
Oct 251.17
Oct 251.18
Oct 251.19
Oct 251.15
Oct 251.17
Sep 251.16
Sep 251.16
Sep 251.16
Sep 251.2
Aug 251.18
Aug 251.15
Aug 251.1
Aug 251.06
Aug 251.03
Jul 251.09
Jul 251.12
Jul 251.14
Jul 251.16
Jun 251.14
Jun 251.18
Jun 251.21
Jun 251.21
May 251.21
May 251.16
May 251.2
May 251.17
May 251.17
Apr 251.1
Apr 251.07
Apr 251.05
Apr 251.11
Mar 251.18
Mar 251.18
Mar 251.16
Mar 251.21
Feb 251.22
Feb 251.18
Feb 251.07
Feb 251.06
Jan 251.04
Jan 251.05
Jan 251.05
Jan 251.03
Jan 251.12
Dec 241.13
Dec 241.13
Dec 241.19
Dec 241.2
Nov 241.24
Nov 241.26
Nov 241.24
Nov 241.28
Nov 241.15
Oct 241.15
Centerspace
CSR
Stockpicker

Video analysis: CSR

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CSR

New Strong Sell Stocks for September 11th

zacks.com · 11 Sep 2026

New Strong Sell Stocks for September 11th

DKS, AU and CSR have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2026.

Centerspace Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centerspace - CSR

gurufocus.com · 10 Sep 2026

Centerspace Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centerspace - CSR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propos

Centerspace Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centerspace - CSR

businesswire.com · 10 Sep 2026

Centerspace Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centerspace - CSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centerspace (NYSE: CSR) to Independence Realty Trust, Inc. (NYSE: IRT). Under the terms of the proposed transaction, shareholders of Centerspace will receive 3.800 shares of Independence Realty common stock for each share of Centerspace that they own. KSF is seeking to determine whether this conside.

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

globenewswire.com · 10 Sep 2026

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma

Why Independence Realty Trust Stock Sank Today

fool.com · 9 Sep 2026

Why Independence Realty Trust Stock Sank Today

It's essentially acquiring a peer REIT.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centerspace (NYSE: CSR)

prnewswire.com · 9 Sep 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centerspace (NYSE: CSR)

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.

Are CSR, BZH, IRT Obtaining Fair Deals for their Shareholders?

gurufocus.com · 9 Sep 2026

Are CSR, BZH, IRT Obtaining Fair Deals for their Shareholders?

Are CSR, BZH, IRT Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 9, 2026

Centerspace (CSR) M&A Call Transcript

seekingalpha.com · 9 Sep 2026

Centerspace (CSR) M&A Call Transcript

Centerspace (CSR) M&A Call Transcript

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.